 Mark Gregory
Concepts (188)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| fms-Like Tyrosine Kinase 3 | 4 | 2022 | 47 | 1.210 |
Why?
| | Proto-Oncogene Proteins c-myc | 7 | 2012 | 139 | 0.900 |
Why?
| | Leukemia, Myeloid, Acute | 3 | 2022 | 622 | 0.790 |
Why?
| | Glutamine | 2 | 2019 | 104 | 0.730 |
Why?
| | Benzothiazoles | 2 | 2017 | 33 | 0.690 |
Why?
| | Phenylurea Compounds | 2 | 2017 | 96 | 0.650 |
Why?
| | Drug Resistance, Neoplasm | 4 | 2022 | 802 | 0.580 |
Why?
| | Oxidation-Reduction | 2 | 2019 | 1069 | 0.570 |
Why?
| | Benzeneacetamides | 1 | 2017 | 7 | 0.560 |
Why?
| | Glutaminase | 1 | 2017 | 11 | 0.560 |
Why?
| | Thiadiazoles | 1 | 2017 | 23 | 0.550 |
Why?
| | Leukemia | 1 | 2019 | 238 | 0.520 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | 2014 | 121 | 0.520 |
Why?
| | Ataxia Telangiectasia Mutated Proteins | 1 | 2016 | 66 | 0.520 |
Why?
| | Gene Expression Regulation, Leukemic | 1 | 2016 | 54 | 0.510 |
Why?
| | Glucosephosphate Dehydrogenase | 1 | 2016 | 60 | 0.500 |
Why?
| | Fusion Proteins, bcr-abl | 3 | 2014 | 69 | 0.470 |
Why?
| | Antineoplastic Agents | 4 | 2023 | 2135 | 0.440 |
Why?
| | Energy Metabolism | 1 | 2019 | 920 | 0.400 |
Why?
| | Xenograft Model Antitumor Assays | 4 | 2019 | 870 | 0.360 |
Why?
| | Philadelphia Chromosome | 1 | 2010 | 18 | 0.340 |
Why?
| | Cell Line, Tumor | 9 | 2022 | 3414 | 0.340 |
Why?
| | Protein Kinase Inhibitors | 6 | 2022 | 916 | 0.330 |
Why?
| | NFATC Transcription Factors | 1 | 2010 | 95 | 0.330 |
Why?
| | Wnt Proteins | 1 | 2010 | 133 | 0.310 |
Why?
| | Glycogen Synthase Kinase 3 | 2 | 2012 | 82 | 0.300 |
Why?
| | Tumor Suppressor Protein p14ARF | 2 | 2005 | 7 | 0.290 |
Why?
| | Apoptosis | 10 | 2022 | 2554 | 0.290 |
Why?
| | Cell Proliferation | 4 | 2019 | 2479 | 0.290 |
Why?
| | Mice, Inbred NOD | 3 | 2017 | 601 | 0.260 |
Why?
| | Calcium | 2 | 2013 | 1198 | 0.230 |
Why?
| | Cell Survival | 3 | 2019 | 1119 | 0.230 |
Why?
| | RNA, Small Interfering | 4 | 2016 | 622 | 0.220 |
Why?
| | Ubiquitins | 2 | 2000 | 36 | 0.210 |
Why?
| | Cysteine Endopeptidases | 2 | 2000 | 72 | 0.210 |
Why?
| | Multienzyme Complexes | 2 | 2000 | 68 | 0.210 |
Why?
| | Mice | 12 | 2019 | 17774 | 0.200 |
Why?
| | Cell Nucleus | 2 | 2003 | 617 | 0.200 |
Why?
| | Mice, Transgenic | 2 | 2019 | 2164 | 0.200 |
Why?
| | Burkitt Lymphoma | 2 | 2000 | 60 | 0.200 |
Why?
| | Peptide Hydrolases | 1 | 2003 | 111 | 0.200 |
Why?
| | Cyclosporine | 3 | 2014 | 268 | 0.200 |
Why?
| | Genes, myc | 2 | 2012 | 48 | 0.200 |
Why?
| | Animals | 15 | 2019 | 36862 | 0.180 |
Why?
| | Epididymis | 1 | 2000 | 12 | 0.170 |
Why?
| | Hormones | 1 | 2000 | 142 | 0.160 |
Why?
| | Cell Division | 2 | 2004 | 796 | 0.160 |
Why?
| | Transcriptome | 1 | 2025 | 972 | 0.150 |
Why?
| | Head and Neck Neoplasms | 1 | 2023 | 605 | 0.140 |
Why?
| | Phosphorylation | 6 | 2022 | 1759 | 0.140 |
Why?
| | Hydrazines | 1 | 2016 | 35 | 0.130 |
Why?
| | Transfection | 4 | 2004 | 947 | 0.130 |
Why?
| | Liver | 1 | 2025 | 1941 | 0.130 |
Why?
| | Reactive Oxygen Species | 1 | 2019 | 622 | 0.120 |
Why?
| | Molecular Targeted Therapy | 1 | 2019 | 413 | 0.120 |
Why?
| | Signal Transduction | 5 | 2016 | 5078 | 0.120 |
Why?
| | Glutamic Acid | 1 | 2017 | 248 | 0.120 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2014 | 1688 | 0.120 |
Why?
| | Oligomycins | 1 | 2014 | 7 | 0.120 |
Why?
| | Mitochondrial Proton-Translocating ATPases | 1 | 2014 | 19 | 0.120 |
Why?
| | RNA Interference | 2 | 2014 | 467 | 0.110 |
Why?
| | Threonine | 2 | 2012 | 46 | 0.110 |
Why?
| | Imatinib Mesylate | 2 | 2014 | 79 | 0.110 |
Why?
| | Dasatinib | 2 | 2014 | 54 | 0.110 |
Why?
| | Tumor Cells, Cultured | 2 | 2010 | 954 | 0.110 |
Why?
| | Calcineurin Inhibitors | 1 | 2014 | 72 | 0.110 |
Why?
| | Thiazoles | 2 | 2014 | 123 | 0.110 |
Why?
| | Drug Therapy, Combination | 1 | 2016 | 1063 | 0.100 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 2 | 2012 | 234 | 0.100 |
Why?
| | Flow Cytometry | 3 | 2014 | 1184 | 0.100 |
Why?
| | Survival Analysis | 1 | 2016 | 1321 | 0.100 |
Why?
| | Humans | 18 | 2025 | 137294 | 0.100 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 3 | 2012 | 69 | 0.100 |
Why?
| | Gene Expression Regulation | 2 | 2004 | 2608 | 0.100 |
Why?
| | Benzimidazoles | 1 | 2013 | 168 | 0.090 |
Why?
| | Cell Line | 4 | 2005 | 2841 | 0.090 |
Why?
| | Blotting, Western | 2 | 2012 | 1226 | 0.090 |
Why?
| | Disease Models, Animal | 2 | 2019 | 4284 | 0.090 |
Why?
| | Pyrimidines | 2 | 2014 | 471 | 0.090 |
Why?
| | Hematologic Neoplasms | 1 | 2013 | 155 | 0.090 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2005 | 530 | 0.080 |
Why?
| | COS Cells | 2 | 2000 | 188 | 0.080 |
Why?
| | Cell Transformation, Neoplastic | 3 | 2012 | 327 | 0.080 |
Why?
| | Amino Acid Substitution | 3 | 2012 | 309 | 0.080 |
Why?
| | Benzamides | 1 | 2010 | 217 | 0.080 |
Why?
| | Proteasome Endopeptidase Complex | 2 | 2000 | 155 | 0.080 |
Why?
| | Neoplasm Proteins | 2 | 2004 | 434 | 0.080 |
Why?
| | Mitosis | 2 | 2000 | 193 | 0.080 |
Why?
| | Tumor Microenvironment | 2 | 2023 | 674 | 0.080 |
Why?
| | Female | 7 | 2025 | 73052 | 0.070 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 976 | 0.070 |
Why?
| | Piperazines | 1 | 2010 | 350 | 0.070 |
Why?
| | Mice, Inbred C57BL | 3 | 2014 | 5753 | 0.070 |
Why?
| | Colorectal Neoplasms | 1 | 2013 | 793 | 0.060 |
Why?
| | Immunosuppressive Agents | 1 | 2010 | 890 | 0.060 |
Why?
| | Hepatocytes | 1 | 2025 | 220 | 0.050 |
Why?
| | Binding Sites | 2 | 2004 | 1309 | 0.050 |
Why?
| | Ubiquitin | 1 | 2003 | 66 | 0.050 |
Why?
| | Enzyme Inhibitors | 2 | 2023 | 839 | 0.050 |
Why?
| | Transcriptional Activation | 1 | 2005 | 378 | 0.050 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2004 | 313 | 0.050 |
Why?
| | Everolimus | 1 | 2022 | 91 | 0.050 |
Why?
| | RNA, Messenger | 1 | 2010 | 2839 | 0.050 |
Why?
| | Cytokines | 1 | 2010 | 2090 | 0.050 |
Why?
| | Single-Cell Analysis | 1 | 2025 | 311 | 0.050 |
Why?
| | Middle Aged | 3 | 2025 | 33310 | 0.050 |
Why?
| | Mutation | 3 | 2022 | 3956 | 0.050 |
Why?
| | Oxidative Phosphorylation | 1 | 2022 | 193 | 0.050 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2005 | 1399 | 0.040 |
Why?
| | Growth Inhibitors | 1 | 2000 | 43 | 0.040 |
Why?
| | Protein Binding | 2 | 2004 | 2225 | 0.040 |
Why?
| | Adrenal Glands | 1 | 2000 | 78 | 0.040 |
Why?
| | DNA, Complementary | 1 | 2000 | 271 | 0.040 |
Why?
| | Cysteine Proteinase Inhibitors | 1 | 2000 | 49 | 0.040 |
Why?
| | Amino Acid Sequence | 2 | 2004 | 2147 | 0.040 |
Why?
| | 3T3 Cells | 1 | 2000 | 163 | 0.040 |
Why?
| | Pituitary Gland | 1 | 2000 | 149 | 0.040 |
Why?
| | Organ Specificity | 1 | 2000 | 304 | 0.040 |
Why?
| | Mammary Glands, Animal | 1 | 2000 | 129 | 0.040 |
Why?
| | Sequence Deletion | 1 | 2000 | 183 | 0.040 |
Why?
| | Molecular Sequence Data | 2 | 2004 | 2904 | 0.040 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2022 | 412 | 0.040 |
Why?
| | Uterus | 1 | 2000 | 215 | 0.040 |
Why?
| | Prostate | 1 | 2000 | 175 | 0.040 |
Why?
| | Myeloid Cell Leukemia Sequence 1 Protein | 2 | 2012 | 41 | 0.040 |
Why?
| | Tubulin | 1 | 2000 | 140 | 0.040 |
Why?
| | CHO Cells | 2 | 2012 | 161 | 0.040 |
Why?
| | Cricetinae | 2 | 2012 | 289 | 0.040 |
Why?
| | Ovary | 1 | 2000 | 221 | 0.040 |
Why?
| | Protein Processing, Post-Translational | 1 | 2000 | 467 | 0.040 |
Why?
| | Recombinant Fusion Proteins | 1 | 2000 | 664 | 0.040 |
Why?
| | Gene Expression Profiling | 1 | 2025 | 1774 | 0.040 |
Why?
| | Protein Structure, Tertiary | 2 | 2012 | 867 | 0.030 |
Why?
| | Nerve Tissue Proteins | 1 | 2000 | 596 | 0.030 |
Why?
| | Rats | 2 | 2004 | 5639 | 0.030 |
Why?
| | Fibroblasts | 1 | 2000 | 993 | 0.030 |
Why?
| | Dihydrolipoyllysine-Residue Acetyltransferase | 1 | 2014 | 6 | 0.030 |
Why?
| | Ketone Oxidoreductases | 1 | 2014 | 7 | 0.030 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2014 | 71 | 0.030 |
Why?
| | Precipitin Tests | 2 | 2004 | 100 | 0.030 |
Why?
| | Superoxides | 1 | 2014 | 202 | 0.030 |
Why?
| | Drug Synergism | 1 | 2014 | 383 | 0.030 |
Why?
| | S-Phase Kinase-Associated Proteins | 1 | 2012 | 20 | 0.030 |
Why?
| | Early Growth Response Protein 1 | 1 | 2012 | 27 | 0.030 |
Why?
| | MAP Kinase Kinase Kinases | 1 | 2013 | 73 | 0.030 |
Why?
| | Binding, Competitive | 1 | 2012 | 203 | 0.020 |
Why?
| | Transcription, Genetic | 2 | 2012 | 1456 | 0.020 |
Why?
| | Vinblastine | 1 | 2012 | 71 | 0.020 |
Why?
| | Ubiquitination | 1 | 2012 | 102 | 0.020 |
Why?
| | Cytarabine | 1 | 2012 | 61 | 0.020 |
Why?
| | Peptide Mapping | 2 | 2004 | 64 | 0.020 |
Why?
| | Mitochondrial Proteins | 1 | 2014 | 256 | 0.020 |
Why?
| | Gene Knockout Techniques | 1 | 2012 | 117 | 0.020 |
Why?
| | ras Proteins | 1 | 2013 | 153 | 0.020 |
Why?
| | Etoposide | 1 | 2012 | 157 | 0.020 |
Why?
| | Protein Stability | 1 | 2012 | 177 | 0.020 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2012 | 376 | 0.020 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2013 | 267 | 0.020 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2014 | 434 | 0.020 |
Why?
| | Wnt Signaling Pathway | 1 | 2013 | 192 | 0.020 |
Why?
| | Calcium Signaling | 1 | 2013 | 249 | 0.020 |
Why?
| | HeLa Cells | 1 | 2012 | 637 | 0.020 |
Why?
| | Cisplatin | 1 | 2012 | 319 | 0.020 |
Why?
| | Proto-Oncogene Proteins | 1 | 2013 | 647 | 0.020 |
Why?
| | Male | 3 | 2025 | 67560 | 0.020 |
Why?
| | Brain | 1 | 2000 | 2675 | 0.020 |
Why?
| | Mitochondria | 1 | 2014 | 947 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2014 | 3009 | 0.020 |
Why?
| | Genomics | 1 | 2013 | 792 | 0.020 |
Why?
| | Aged | 1 | 2025 | 23851 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2012 | 4197 | 0.010 |
Why?
| | Okadaic Acid | 1 | 2004 | 14 | 0.010 |
Why?
| | Tetradecanoylphorbol Acetate | 1 | 2004 | 150 | 0.010 |
Why?
| | Carcinogens | 1 | 2004 | 124 | 0.010 |
Why?
| | Paclitaxel | 1 | 2004 | 227 | 0.010 |
Why?
| | Dogs | 1 | 2004 | 411 | 0.010 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2004 | 190 | 0.010 |
Why?
| | Protein Kinase C | 1 | 2004 | 261 | 0.010 |
Why?
| | Gene Deletion | 1 | 2004 | 392 | 0.010 |
Why?
| | Enzyme Activation | 1 | 2004 | 813 | 0.010 |
Why?
| | MAP Kinase Signaling System | 1 | 2004 | 321 | 0.010 |
Why?
| | Cell Cycle | 1 | 2004 | 601 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2004 | 2052 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2014 | 10800 | 0.010 |
Why?
| | Phosphoproteins | 1 | 2000 | 338 | 0.010 |
Why?
| | Microtubules | 1 | 2000 | 270 | 0.010 |
Why?
| | Time Factors | 1 | 2004 | 6818 | 0.010 |
Why?
| | Adult | 1 | 2014 | 37724 | 0.010 |
Why?
|
|
Gregory's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|